Condition: Relapsing Remitting Multiple Sclerosis (RRMS) · Sponsor: Novartis Pharmaceuticals
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Calgary, Alberta, Canada | Recruiting |
| Novartis Investigative Site | Calgary, Alberta, Canada | Recruiting |
| Novartis Investigative Site | Edmonton, Alberta, Canada | Recruiting |
| Novartis Investigative Site | Burnaby, British Columbia, Canada | Recruiting |
| Novartis Investigative Site | Vancouver, British Columbia, Canada | Recruiting |
| Novartis Investigative Site | St. John's, Newfoundland and Labrador, Canada | Recruiting |
| Novartis Investigative Site | Halifax, Nova Scotia, Canada | Recruiting |
| Novartis Investigative Site | Halifax, Nova Scotia, Canada | Recruiting |
| Novartis Investigative Site | Ottawa, Ontario, Canada | Recruiting |
| Novartis Investigative Site | Montreal, Quebec, Canada | Recruiting |
| Novartis Investigative Site | Montreal, Quebec, Canada | Recruiting |
| Novartis Investigative Site | Montreal, Quebec, Canada | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06733922